News

Details

Published: 26 September 2019

• portfolio-news

Adrenomed announced today the successful completion of patient enrollment in the proof-of-concept Phase II trial, AdrenOSS-2, evaluating Adrecizumab in patients with early septic shock. Adrecizumab is a first-in-class antibody targeting the vasoprotective peptide Adrenomedullin to restore and maintain vascular integrity in life-threatening conditions associated with vascular leakage, congestion and shock. 

Details

Published: 23 September 2019

• portfolio-news

Confo Therapeutics today announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. Confo Therapeutics is building a portfolio of new medicines based on its proprietary Confo® technology. The technology makes use of antibody fragments or “ConfoBodiesTM” to stabilize G-protein coupled receptors (GPCRs) in their functional conformation, providing a superior starting point for drug design.

Details

Published: 18 September 2019

• portfolio-news

Themis announced today the closing of a Series D financing round totaling EUR 40 million (USD 44 million). The proceeds from this Series D round will be used to accelerate the company’s pivotal Phase 3 clinical trial program for its Chikungunya vaccine and to support further expansion into oncology indications using its proprietary measles vaccine vector platform. Concurrent with the financing, Dr. Walter Stockinger, Managing Partner at Hadean Ventures, will join Themis’ Supervisory Board.